Last reviewed · How we verify
ARRY-382, cFMS inhibitor; oral
cFMS inhibitor
cFMS inhibitor Used for Solid tumors.
At a glance
| Generic name | ARRY-382, cFMS inhibitor; oral |
|---|---|
| Sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
| Drug class | cFMS inhibitor |
| Target | cFMS |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
cFMS is a receptor tyrosine kinase involved in the regulation of cell growth and survival. Inhibiting cFMS has been shown to have anti-tumor effects in various cancers.
Approved indications
- Solid tumors
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: